Article Text

SAT0484 Minimum Diagnostic Standards for Children with Raynaud’s Phenomenon - Results of the Consensus Meeting in Hamburg (Germany) on December 9, 2012
  1. T. Constantin1,
  2. C. Pain2,
  3. N. Toplak3,
  4. M. Moll4,
  5. C. Iking-Konert5,
  6. D. Piotto6,
  7. N. Aktay7,
  8. D. Nemcova8,
  9. P. Hoeger9,
  10. M. Cutolo10,
  11. V. Smith11,
  12. I. Foeldvari for the Juvenile Scleroderma Working Group of PReS12
  1. 1Semmelweis University, Budapest, Hungary
  2. 2Alder Hey Children’s Hospital, Liverpool, United Kingdom
  3. 3University Children’s Hospital Ljubljana, Ljubljana, Slovenia
  4. 4University Childrens Hospital Tuebingen, Tübingen
  5. 5Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
  6. 6Universidade Federal de São Paulo, São Paulo, Brazil
  7. 7Sultan Süleyman Education and Research Hospital, Istanbul, Turkey
  8. 8Children Hospital Prague, Prague, Czech Republic
  9. 9Wilhelmstift Hospital for Sick Children, Hamburg, Germany
  10. 10University Medical School of Genova, Genova, Italy
  11. 11Gent University Hospital, Gent, Belgium
  12. 12Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany


Background Raynaud’s phenomenon (RP) can be the first symptom of a connective tissue disease in children, in particular juvenile systemic scleroderma (JSSC) or systemic lupus erythematosis (SLE). However, the prevalence of RP in healthy school children has been shown to be as high as 15%[1]. There are currently no guidelines or agreed management strategies amongst Paediatric Rheumatologists on how to differentiate primary from secondary RP or how often patients require evaluation.

Objectives To develop consensus standards for good clinical practice for children with RP.

Methods A consensus meeting was organized in the frame of the PRES scleroderma working group. A nominal group technique was used. 75% consensus was defined as agreement.

Results The following agreements were reached:

  1. All patients with RP should be screened with an ANA test.

  2. All ANA positive patients should be screened for scleroderma-specific antibodies (e.g. anti-SCL 70 and anti-centromere antibodies).

  3. All patients with RP should be investigated by capillaroscopy. Capillaroscopy will be classified into “normal”, “aspecific changes” or “scleroderma pattern”.

  4. All patients who have additional symptoms pointing to a definite connective tissue disease should be evaluated according to disease specific guidelines.

  5. ANA-negative and capillaroscopy-negative patients should be followed-up at least every 6 months.

  6. ANA positive patients without disease-specific antibodies and with negative capillaroscopy findings should be followed-up at least every 6 months.

  7. ANA and disease-specific antibody positive patients should have organ specific evaluation according to symptoms, examination and relevant to that particular disease e.g. patients who are ANA and Scl-70 positive may need organ specific evaluation for JSSC as per the Juvenile systemic sclerosis inception cohort protocol (

  8. ANA-positive patients, who have no disease specific antibody but have positive capillaroscopy results, should be followed-up at least every 3 months.

  9. ANA-negative patients with positive capillaroscopy result should be followed-up at least every 6 months.

  10. The group could not reach an agreement regarding treatment, due to a lack of data for the paediatric age group. The group agreed that implementation of adult recommendations for paediatric care might be reasonable, but robust paediatric trials are needed.

Conclusions The group made a suggestion for a standard of good clinical practice for RP in children. Our aim is that this will facilitate a large multicentre prospective follow-up study of children with RP.


  1. Jones, G.T., et al., Occurrence of Raynaud’s phenomenon in children ages 12-15 years: prevalence and association with other common symptoms. Arthritis Rheum, 2003. 48(12): p. 3518-21.


Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.